(Q43986819)

28 November 2017

title

Clinical significance of telomerase activity in multiple myeloma (English)

1 reference

28 November 2017

7

Naokuni Uike

1 reference

28 November 2017

Motoaki Shiratsuchi

1

1 reference

28 November 2017

Koichiro Muta

2

1 reference

28 November 2017

Yasunobu Abe

3

1 reference

28 November 2017

Seiichi Motomura

4

1 reference

28 November 2017

Fumihiro Taguchi

5

1 reference

28 November 2017

Hiroshi Takatsuki

6

1 reference

28 November 2017

Tsukuru Umemura

8

1 reference

28 November 2017

Hajime Nawata

9

1 reference

28 November 2017

Junji Nishimura

10

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

94

1 reference

28 November 2017

issue

8

1 reference

28 November 2017

page(s)

2232-2238

1 reference

Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Telomere length, aging, and somatic cell turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Telomerase activity in myeloma cells is closely related to cell cycle status, but not to apoptotic signals induced by interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Telomere lengthening and telomerase activation during human B cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Prognostic factors in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Serum beta2microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Acute phase proteins and prognosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Prognostic factors and staging in multiple myeloma: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10472

21 January 2018

Identifiers

DOI

10.1002/CNCR.10472

1 reference

28 November 2017

1 reference